Coronary/Structural Heart

A New Study From Hello Heart Shows Surprising Findings on Walking Patterns and Heart Health

Correlations between lifestyle changes and blood pressure indicate how a person could increase their walking to positively impact heart health MENLO PARK, Calif.–(BUSINESS WIRE)–Hello Heart, the only digital therapeutic that focuses exclusively on heart health, today announced new data on how minor lifestyle and behavioral changes can have a significant […]

Alnylam Submits Supplemental New Drug Application (sNDA) to U.S. Food and Drug Administration (FDA) for ONPATTRO® (patisiran)

– sNDA Submission is Based on Findings from the APOLLO-B Phase 3 Study That Showed Patisiran Demonstrated Significant Improvement on Functional Capacity, Health Status and Quality of Life Compared to Placebo at Month 12 – – Study Also Demonstrated Encouraging Safety Profile in Patients with Cardiomyopathy of ATTR Amyloidosis – […]

Provident Healthcare Partners Advises Southwest Cardiovascular Associates in its Partnership with Cardiovascular Associates of America

BOSTON and NEW YORK, Dec. 8, 2022 /PRNewswire/ — Provident Healthcare Partners (“Provident”), a leading healthcare investment banking firm, announced it has advised Southwest Cardiovascular Associates (“SWCVA” or “Company”) in its partnership with Cardiovascular Associates of America (“CVAUSA”), a portfolio company of Webster Equity Partners. SWCVA provides interventional and diagnostic cardiology services throughout its three-location footprint […]

Primary endpoint met in the CLEAR Outcomes Trial of bempedoic acid showing statistically significant relative risk reduction in major adverse CV events

Successful topline results from the CLEAR Outcomes Trial demonstrate that bempedoic acid, marketed as NILEMDO®▼ in Europe, reduces the risk of serious cardiovascular (CV) events in patients with, or who are at, high risk for atherosclerotic cardiovascular disease (ASCVD) with elevated LDL-C levels1,2 The results position bempedoic acid as the […]

EDWARDS LIFESCIENCES OUTLINES GROWTH STRATEGY AT ANNUAL INVESTOR CONFERENCE

IRVINE, Calif., Dec. 8, 2022 /PRNewswire/ — Edwards Lifesciences Corporation (NYSE: EW) will discuss the company’s strategy for longer-term growth, provide an update on its technology pipeline and share its financial guidance1 today during its annual investor conference. Highlights of today’s conference include: Global market opportunity across 4 product groups projected to double to […]

Cytokinetics Announces Initiation of Phase 1 Clinical Study of CK-3828136

Advancement of Novel Cardiac Troponin Activator Expands Cardiovascular Franchise for Conditions Associated with Impaired Cardiac Contractility SOUTH SAN FRANCISCO, Calif., Dec. 07, 2022 (GLOBE NEWSWIRE) — Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that the first participants have been dosed in a Phase 1 randomized, double-blind, placebo-controlled, single and multiple ascending […]

Esperion Announces CLEAR Cardiovascular Outcomes Trial of NEXLETOL® (bempedoic acid) Meets Primary Endpoint

– Demonstrates statistically significant and clinically meaningful results – – Bempedoic acid becomes the first ATP citrate lyase inhibitor and first oral non-statin to meet the major adverse cardiovascular events (MACE-4) primary endpoint –                   – Presentation of comprehensive data at a key medical conference in the first quarter of 2023 – ANN ARBOR, […]

Amarin Announces VAZKEPA® (icosapent ethyl) Receives Regulatory Approval in Switzerland

— Amarin Continuing Process for Obtaining National Pricing and Reimbursement in Switzerland in the Course of 2023 — — Swissmedic Approval Underpins Company’s Presence and Expansion in Switzerland as its Regional Commercial Hub for Europe — DUBLIN, Ireland and BRIDGEWATER, N.J., Dec. 07, 2022 (GLOBE NEWSWIRE) — Amarin Corporation plc […]

CORVIA MEDICAL ANNOUNCES RANDOMIZATION OF FIRST PATIENT IN THE RESPONDER-HF CONFIRMATORY TRIAL

Corvia® Atrial Shunt has the potential to change the way heart failure is treated TEWKSBURY, Mass., Dec. 6, 2022 /PRNewswire/ — Corvia Medical, Inc., a company dedicated to transforming the treatment of heart failure (HF), announced the first patient has been randomized in RESPONDER-HF, a global confirmatory trial of the Corvia Atrial Shunt […]

Ultromics receives FDA Clearance for its Breakthrough Device EchoGo Heart Failure: An AI-based platform that enables precision detection of heart failure with preserved ejection fraction

EchoGo® Heart Failure revolutionizes the detection of HFpEF – the biggest unmet need in cardiovascular medicine.1 OXFORD, England, Dec. 6, 2022 /PRNewswire/ — Ultromics’ EchoGo® Heart Failure, an AI solution for echocardiography with the potential to revolutionize the diagnosis of heart failure with preserved ejection fraction (HFpEF), has received US Food and Drug […]